Bladder Cancer Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Bristol-Myers Squibb Company, GlaxoSmithKline PLC., Johnson & Johnson, Janssen Pharma, F. Hoffmann-La Roche., Merck

DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bladder Cancer, historical and forecasted epidemiology as well as the Bladder Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Bladder Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bladder Cancer Market Forecast
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Bladder Cancer Market Report:
• The Bladder cancer market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In January 2025, Preliminary findings from an ongoing study at the Christie Hospital in Manchester provide encouraging support for an investigational therapy targeting the most common type of bladder cancer-urothelial carcinoma. The Christie reported promising patient responses to the new targeted chemotherapy, which is designed to identify and bind to a specific protein present on the surface of certain tumor cells.
• In January 2025, Pfizer has announced that its Phase III CREST trial assessing sasanlimab in combination with Bacillus Calmette-Guérin (BCG) for induction treatment-with or without maintenance therapy-in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC) has successfully achieved its primary endpoint of event-free survival (EFS).
• In January 2025, The FDA approved the Investigational New Drug (IND) application for TYRA-300, an oral FGFR3-selective inhibitor, intended for treating low-grade, intermediate-risk non-muscle-invasive bladder cancer (NMIBC). This clearance enables the initiation of a Phase 2 clinical trial evaluating TYRA-300 in this specific patient group.
• In October 2024, Johnson & Johnson, a US-based pharmaceutical firm, has halted its Phase III SunRISe-2 trial evaluating TAR-200 in patients with muscle-invasive bladder cancer (MIBC) who are not undergoing radical cystectomy. The discontinuation follows a recommendation from an independent data monitoring committee after a planned interim analysis. The study was designed to compare the effectiveness of TAR-200 combined with cetrelimab versus standard chemoradiotherapy
• An Estimated 573,278 people were diagnosed with Bladder Cancer WorldWide in 2020
• Bladder Cancer is the fourth most common cancer among the men
• There has been a decline of 1%/year in the number of cases of Bladder Cancer in the US from 2009-to 2018
• Bladder cancer was rated 10th among all cancers in the globe, with 549,000 new cases and 200,000 deaths each year
• While the specific aetiology of bladder cancer is unknown, it has been related to a number of risk factors, including tobacco use and exposure to certain chemicals and gases. In addition, persons who have a family history of bladder cancer are more likely to get the disease.
• Key Bladder Cancer Companies: Bristol-Myers Squibb Company, GlaxoSmithKline PLC., Johnson & Johnson (Janssen Pharmaceutical), F. Hoffmann-La Roche., Merck & Co. Inc., and others
• Key Bladder Cancer Therapies: VPM1002BC, Ascorbic Acid, Avelumab, Cisplatin, Paclitaxel, Mitomycin C, N-803 and BCG, and others

Got queries? Click here to know more about the Bladder Cancer Market Landscape.
https://www.delveinsight.com/report-store/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bladder Cancer Overview:
Urine is stored in the bladder, which is a hollow organ in the lower abdomen. Bladder cancer develops in the bladder's lining. Transitional cell carcinoma, commonly known as urothelial carcinoma, is the most frequent type of bladder cancer. Smoking is one of the leading causes of bladder cancer. Bladder cancer is frequently detected in its early stages.

Bladder Cancer Market:
The dynamics of the Bladder Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as and others during the forecast period 2024-2034.
"The key players working in the field of Bladder Cancer are the - Swiss Group for Clinical Cancer Research, University of Kansas Medical Center, University of Oklahoma, Radiation Therapy Oncology Group, National Cancer Institute (NCI), and ImmunityBio, Inc., and others."

Bladder Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bladder Cancer Epidemiology Segmentation:
The Bladder Cancer market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Bladder Cancer
• Prevalent Cases of Bladder Cancer by severity
• Gender-specific Prevalence of Bladder Cancer
• Diagnosed Cases of Episodic and Chronic Bladder Cancer

Download the report to understand which factors are driving Bladder Cancer epidemiology trends @ Bladder Cancer Epidemiology Forecast
https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bladder Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bladder Cancer market or expected to get launched during the study period. The analysis covers Bladder Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Bladder Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Emerging Bladder Cancer Drugs Under Different Phases of Clinical Development Include:
• TL-532: Tollys
• AU-011: Aura Biosciences
• TARA-002: Protara Therapeutics
• VAX 014: Vaxiion Therapeutics
• Pemigatinib: Incyte Corporation
• Erdafitinib: Janssen Pharmaceuticals
• TLD 1433: Theralase Technologies
• PF-06801591: Pfizer
• Nivolumab: BristolMyers Squibb
• APL-1202: Asieris Pharmaceuticals

Discover more about therapies set to grab major Bladder Cancer market share @ Bladder Cancer Treatment Landscape
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Bladder Cancer Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bladder Cancer Companies: Bristol-Myers Squibb Company., GlaxoSmithKline PLC., Johnson & Johnson (Janssen Pharmaceutical), F. Hoffmann-La Roche., Merck & Co. Inc., and others, and others
• Key Bladder Cancer Therapies: VPM1002BC, Ascorbic Acid, Avelumab, Cisplatin, Paclitaxel, Mitomycin C, N-803 and BCG, and others
• Bladder Cancer Therapeutic Assessment: Bladder Cancer current marketed and Bladder Cancer emerging therapies
• Bladder Cancer Market Dynamics: Bladder Cancer market drivers and Bladder Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bladder Cancer Unmet Needs, KOL's views, Analyst's views, Bladder Cancer Market Access and Reimbursement

To know more about Bladder Cancer companies working in the treatment market, visit @ Bladder Cancer Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/bladder-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Bladder Cancer Patient Share (%) Overview at a Glance
5. Bladder Cancer Market Overview at a Glance
6. Bladder Cancer Disease Background and Overview
7. Bladder Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Bladder Cancer
9. Bladder Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Bladder Cancer Emerging Therapies
12. Bladder Cancer Market Outlook
13. Country-Wise Bladder Cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Bladder Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Latest Reports Offered By DelveInsight:
• Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight
• Erectile Dysfunction Market: https://www.delveinsight.com/report-store/erectile-dysfunction-market
• Necrotizing Enterocolitis Market: https://www.delveinsight.com/sample-request/necrotizing-enterocolitis-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.